Literature DB >> 30846101

von Willebrand Factor and Management of Heart Valve Disease: JACC Review Topic of the Week.

Eric Van Belle1, Flavien Vincent1, Antoine Rauch2, Caterina Casari3, Emmanuelle Jeanpierre2, Valentin Loobuyck4, Mickael Rosa5, Cedric Delhaye6, Hughes Spillemaeker6, Camille Paris2, Nicolas Debry6, Basile Verdier6, André Vincentelli4, Annabelle Dupont5, Peter J Lenting3, Sophie Susen7.   

Abstract

For decades, numerous observations have shown an intimate relationship between von Willebrand factor (VWF) multimer profile and heart valve diseases (HVD). The current knowledge of the unique biophysical properties of VWF helps us to understand the longstanding observations concerning the bleeding complications in patients with severe HVD. Not only does the analysis of the VWF multimer profile provide an excellent evaluation of HVD severity, it is also a strong predictor of clinical events. Also of importance, VWF responds within minutes to any significant change in hemodynamic valve status, making it an accurate marker of the quality of surgical and transcatheter therapeutic interventions. The authors provide in this review a practical, comprehensive, and evidence-based framework of the concept of VWF as a biomarker in HVD, advocating for its implementation into the clinical decision-making process besides usual clinical and imaging evaluation. They also delineate critical knowledge gaps and research priorities to definitely validate this concept.
Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  aortic stenosis; biomarker; bioprosthesis heart valve disease; mitral regurgitation; paravalvular regurgitation; point-of-care test; transcatheter aortic valve replacement; von Willebrand factor

Mesh:

Substances:

Year:  2019        PMID: 30846101     DOI: 10.1016/j.jacc.2018.12.045

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  10 in total

1.  Plasma levels of von Willebrand factor and future risk of incident venous thromboembolism.

Authors:  Magnus S Edvardsen; Kristian Hindberg; Ellen-Sofie Hansen; Vânia M Morelli; Thor Ueland; Pål Aukrust; Sigrid K Brækkan; Line H Evensen; John-Bjarne Hansen
Journal:  Blood Adv       Date:  2021-01-12

2.  The impact of bicuspid aortic valve morphology on von Willebrand factor function in patients with severe aortic stenosis and its change after TAVI.

Authors:  Carsten Jungbauer; Kurt Debl; Nastasia Roth; Carolin Heidel; Congde Xu; Ute Hubauer; Stefan Wallner; Christine Meindl; Andreas Holzamer; Michael Hilker; Marcus Creutzenberg; Samuel Sossalla; Lars Maier
Journal:  Clin Res Cardiol       Date:  2022-07-15       Impact factor: 6.138

Review 3.  Mechanisms and Drug Therapies of Bioprosthetic Heart Valve Calcification.

Authors:  Shuyu Wen; Ying Zhou; Wai Yen Yim; Shijie Wang; Li Xu; Jiawei Shi; Weihua Qiao; Nianguo Dong
Journal:  Front Pharmacol       Date:  2022-06-03       Impact factor: 5.988

Review 4.  Circulating Monocyte Subsets and Transcatheter Aortic Valve Replacement.

Authors:  Fanny Lassalle; Mickael Rosa; Bart Staels; Eric Van Belle; Sophie Susen; Annabelle Dupont
Journal:  Int J Mol Sci       Date:  2022-05-10       Impact factor: 6.208

5.  Pre-procedural abnormal function of von Willebrand Factor is predictive of bleeding after surgical but not transcatheter aortic valve replacement.

Authors:  Kajetan Grodecki; Karol Zbroński; Elżbieta Przybyszewska-Kazulak; Anna Olasińska-Wiśniewska; Radosław Wilimski; Bartosz Rymuza; Piotr Scisło; Paweł Czub; Dominika Koper; Janusz Kochman; Katarzyna Pawlak; Olga Ciepiela; Marek Grygier; Marek Jemielity; Maciej Lesiak; Krzysztof J Filipiak; Grzegorz Opolski; Zenon Huczek
Journal:  J Thromb Thrombolysis       Date:  2019-11       Impact factor: 2.300

6.  Novel insights into the molecular basis of calcific aortic valve disease.

Authors:  Jaana Rysä
Journal:  J Thorac Dis       Date:  2020-11       Impact factor: 2.895

Review 7.  Platelets: Implications in Aortic Valve Stenosis and Bioprosthetic Valve Dysfunction From Pathophysiology to Clinical Care.

Authors:  Stephanie L Sellers; Gaurav S Gulsin; Devyn Zaminski; Rong Bing; Azeem Latib; Janarthanan Sathananthan; Philippe Pibarot; Rihab Bouchareb
Journal:  JACC Basic Transl Sci       Date:  2021-11-17

Review 8.  Models and Techniques to Study Aortic Valve Calcification in Vitro, ex Vivo and in Vivo. An Overview.

Authors:  Maria Bogdanova; Arsenii Zabirnyk; Anna Malashicheva; Daria Semenova; John-Peder Escobar Kvitting; Mari-Liis Kaljusto; Maria Del Mar Perez; Anna Kostareva; Kåre-Olav Stensløkken; Gareth J Sullivan; Arkady Rutkovskiy; Jarle Vaage
Journal:  Front Pharmacol       Date:  2022-06-02       Impact factor: 5.988

Review 9.  Multimodal Treatment and Diagnostic Modalities in the Setting of Heyde's Syndrome: A Systematic Review.

Authors:  Dawood Jamil; Hadrian Hoang-Vu Tran; Mafaz Mansoor; Samia Rauf Bbutt; Travis Satnarine; Pranuthi Ratna; Aditi Sarker; Adarsh Srinivas Ramesh; Carlos Munoz Tello; Lubna Mohammed
Journal:  Cureus       Date:  2022-08-16

Review 10.  Shear Stress-Induced Activation of von Willebrand Factor and Cardiovascular Pathology.

Authors:  Sergey Okhota; Ivan Melnikov; Yuliya Avtaeva; Sergey Kozlov; Zufar Gabbasov
Journal:  Int J Mol Sci       Date:  2020-10-21       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.